Dr. Steven Nissen, author of an article on Avandia's risks, makes rounds at the Cleveland Clinic.
(Jim Baron/getty images/for the boston globe)
FDA panel backs diabetes pill linked to heart risk
Dr. Steven Nissen, author of an article on Avandia's risks, makes rounds at the Cleveland Clinic.
(Jim Baron/getty images/for the boston globe)
Avandia, once the world's top-selling diabetes pill, should remain on the market, federal advisers said yesterday, but many recommended that the drug carry stronger warnings about its heart risks. (Full article: 927 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
